- Home
- UNF vs AKRO Comparison
UNF vs AKRO Comparison
Compare UNF & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNF
- AKRO
- Stock Information
- Founded
- UNF 1936
- AKRO 2017
- Country
- UNF United States
- AKRO United States
- Employees
- UNF N/A
- AKRO N/A
- Industry
- UNF Business Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- UNF Consumer Discretionary
- AKRO Health Care
- Exchange
- UNF Nasdaq
- AKRO Nasdaq
- Market Cap
- UNF N/A
- AKRO 3.5B
- IPO Year
- UNF N/A
- AKRO 2019
- Fundamental
- Price
- UNF $173.77
- AKRO $42.72
- Analyst Decision
- UNF Hold
- AKRO Strong Buy
- Analyst Count
- UNF 3
- AKRO 9
- Target Price
- UNF $189.67
- AKRO $76.29
- AVG Volume (30 Days)
- UNF 139.4K
- AKRO 954.5K
- Earning Date
- UNF 04-02-2025
- AKRO 05-09-2025
- Dividend Yield
- UNF 0.81%
- AKRO N/A
- EPS Growth
- UNF 30.73
- AKRO N/A
- EPS
- UNF 7.82
- AKRO N/A
- Revenue
- UNF $2,438,814,000.00
- AKRO N/A
- Revenue This Year
- UNF $1.09
- AKRO N/A
- Revenue Next Year
- UNF $3.83
- AKRO N/A
- P/E Ratio
- UNF $22.24
- AKRO N/A
- Revenue Growth
- UNF 6.74
- AKRO N/A
- 52 Week Low
- UNF $149.58
- AKRO $17.86
- 52 Week High
- UNF $243.70
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- UNF 27.30
- AKRO 42.72
- Support Level
- UNF $162.00
- AKRO $41.84
- Resistance Level
- UNF $180.60
- AKRO $46.14
- Average True Range (ATR)
- UNF 5.33
- AKRO 1.96
- MACD
- UNF -3.34
- AKRO -0.24
- Stochastic Oscillator
- UNF 24.50
- AKRO 20.18
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.